Annotation of rs1061624

Genotypes AG + GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype AA.

as measured by PASI75 at 6 months.

From Publication

Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018. Ovejero-Benito María C et al.
PMID:29192552(opens in new window) DOI:10.2217/pgs-2017-0143(opens in new window)

Gene

TNFRSF1B

Variant

rs1061624

Phenotype Category

Efficacy

Association Significance

The study reports this association is significant

PharmGKB ID

1449155535

Score
More info on scoring

2.25

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    Study size

    90

    Association p-value

    = 0.025

    Statistical analysis

    OR: 0.32

    Confidence interval

    0.12 - 0.86

    Biogeographical group
    More info on groups

    European

    Population description

    men; women

    Disease: PASI (PASI75) at 6 months

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...